NOW ENROLLING
A Phase I/II Randomized, Blinded, Placebo Controlled, Safety and Pharmacodynamic Study of BHT-3021 with Open Label Cross-Over
in Subjects with Type 1 Diabetes Mellitus
4/16/08
Bayhill Therapeutics Presents Data From a Phase II Trial of BHT-3009 in Multiple Sclerosis at American Academy of Neurology 60th Annual Meeting
4/10/08
Bayhill Therapeutics’ Announces Presentation of MS Drug Candidate BHT-3009 at American Academy of Neurology 60th Annual Meeting
1/9/08
Bayhill Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering
10/4/07
Bayhill Therapeutics to Present Positive Data from a Phase IIb Trial of BHT-3009 in Multiple Sclerosis
5/14/07
Bayhill Therapeutics Appoints Fred Kurland as Chief Financial Officer
12/4/06
Bayhill Therapeutics Names Paul Westberg Vice President of Business Development
11/15/2006
Bayhill Therapeutics Names Robert S. King Vice President of Manufacturing
5/30/2006
Bayhill doses multiple sclerosis patients with BHT-3009 in a Phase II trial, and reports Phase I trial results at the European Neurological Society meeting in Lausanne, Switzerland
.PDF News Advisory
4/6/2006
Bayhill Therapeutics doses multiple sclerosis patients in a Phase II trial and raises an additional $15.8 million as an extension to its Series B financing
4/6/2006
Former Eli Lilly executive, David E. Thompson, joins Bayhill Therapeutics board of directors
4/4/2006
American Academy of Neurology – News advisory: Presentation of multiple sclerosis research: Phase I/II Trial of a MBP Encoding DNA Plasmid (BHT−3009) Alone or Combined with Atorvastatin for Treatment of Multiple Sclerosis
12/19/2005
ECTRIMS 2005 -
Investigational MS drug down regulates the underlying cause believed responsible for multiple sclerosis
